BS_NH7K4CD9
Posterior Fossa Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Posterior Fossa Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Posterior Fossa Ependymoma
- overall_survival_months
- 66.32720105124835
- age_years
- 1.797
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.318
- TNFA_SIGNALING_VIA_NFKB+0.272
- SPERMATOGENESIS+0.212
- HYPOXIA+0.206
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.197
- ANGIOGENESIS+0.166
- MYOGENESIS+0.165
- COAGULATION+0.119
- APICAL_JUNCTION+0.068
- INFLAMMATORY_RESPONSE+0.060
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.700
- MYC_TARGETS_V1-0.638
- PROTEIN_SECRETION-0.580
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.485
- UNFOLDED_PROTEIN_RESPONSE-0.464
- MTORC1_SIGNALING-0.441
- ADIPOGENESIS-0.414
- MYC_TARGETS_V2-0.409
- ANDROGEN_RESPONSE-0.406
- DNA_REPAIR-0.392
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NH7K4CD9 | EPN | Posterior Fossa EPN | 0.947 |
| 2 | SRR1375271 | GTEX | — | 0.898 |
| 3 | MNG779 | — | — | 0.890 |
| 4 | SRR1430972 | GTEX | — | 0.886 |
| 5 | SRR1390582 | GTEX | — | 0.883 |
| 6 | SRR1444876 | GTEX | — | 0.879 |
| 7 | 82978 | EPN | Supratentorial EPN | 0.874 |
| 8 | SRR6013548 | — | cohortA1 | 0.871 |
| 9 | SRR1489155 | GTEX | — | 0.870 |
| 10 | BS_0XEG6SNV | EPN | Supratentorial EPN | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.318 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.272 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.212 | Inavolisib | — uncovered |
| HYPOXIA | 0.206 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.197 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.166 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.165 | Inavolisib | — uncovered |
| COAGULATION | 0.119 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.068 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.052 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.041 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.011 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.003 | Inavolisib | — uncovered |